Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 22, 2003

View Archived Issues

Adenosine alleviates neuropathic pain in humans

Advantages for insulin/metformin vs. triple oral therapy in type 2 diabetes

Pentostatin in children with chronic GVHD

HDAC inhibitors reported to be potentially useful in controlling cardiac hypertrophy

Antiinflammatory effects described for IS-741 in a rat model of IBD

AVI BioPharma cleared to begin phase Ib trial of West Nile virus antisense drug

Abbott and Millennium end research alliance

Health Canada approves Gamunex

SuperGen discusses Orathecin rolling NDA submission plans with FDA

Genta to acquire Salus Therapeutics

Preliminary results of North American Cystistat trial for interstitial cystitis

Corixa and Apovia enter RC-529 agreement

Engitech to commercialize and market Alferon N in the U.S.

ImClone submits Erbitux BLA

Substance P-derived peptides with NK1-antagonist activity and their use as antitumor agents

Quinazoline-based fungal efflux pump inhibitors newly developed at Essential Therapeutics

Eisai claims novel proteasome inhibitors with utility as antitumor agents

Novel PPARalpha agonists under study at Sigma-Tau

New MMP inhibitors in early development at Leo Pharma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...